Society for Immunotherapy of Cancer (SITC)

Immunotherapy for the treatment of GU Malignancies

Edwin M Posadas, MD FACP Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center

Advances in Cancer Immunotherapy[™] - Los Angeles June 19, 2015



Disclosures

- Research support: BNIT, Tracon
- Honoraria: Medivation, Astellas, Pharamcyclics


Outline

1. General Principles

- 2. Urothelial Carcinomas
- 3. Renal Cell Carcinoma
- 4. Prostate Cancer


Genitourinary Malignancies

Leading Sites of New Cancer Cases and Deaths – 2015 Estimates



Cancer Facts and Figures, 2015

General Principles – Immunotherapy



Cancer Immunotherapy Given the "Breakthrough of the Year" Title.

Science magazine deems advances in cancer immunotherapy as the scientific breakthrough of the year.

Immunotherapy referred to as a "turning point in cancer".

Classes of Immunotherapies

Active


- Vaccines
- IC BCG
- Cytokine Therapy

Passive

- Monoclonal antibody therapy
- Cell-based therapy
 - T cell
 - APC
- Infusion of gamma globulin


What is the nature of the immune response towards tumors?

Tumors fails to elicit immune response.



What is the nature of the immune response towards tumors?


Tumors actively suppress the immune response via 'checkpoint' inhibitors.



Sharma and Allison Science 348:6230, 2015

Checkpoint inhibitors


Tumor cells evade the body's immune system by turning it off by expressing PD-L1, which binds to PD-1 leading to the arrest of the immune response directed against the tumor.



Targeting immune checkpoint inhibitors with monoclonal antibodies

Ipilimumab


FDA approval Jan. 1, 2011.




Outline

- 1. General Principles Immunotherapy
- 2. Urothelial Carcinomas
- 3. Renal Cell Carcinoma
- 4. Prostate Cancer

Urothelial Cancers




Superficial Urothelial Cancers



BCG for refractory tumors

- Bacillus Calmette-Guerin (BCG)
 - Instilled into bladder
 - Prevents recurrence of high risk disease




Urothelial CA- BCG immunotherapy

- 1929- 1st association of TB and cancer
- 1976- first use in superficial bladder cancer
- Mechanism of action unknown


Pearl, AM J Hygeine 1929; Morales, J Urol 1976;

Muscle Invasive Cancer




PD-L1 inhibition in refractory urothelial cancers MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Thomas Powles¹, Joseph Paul Eder², Gregg D. Fine³, Fadi S. Braiteh⁴, Yohann Loriot⁵, Cristina Cruz⁶, Joaquim Bellmunt⁷, Howard A. Burris⁸, Daniel P. Petrylak², Siew-leng Teng³, Xiaodong Shen³, Zachary Boyd³, Priti S. Hegde³, Daniel S. Chen³ & Nicholas J. Vogelzang⁹



Tumour-infiltrating immune cells




Tumour cells

	Objective response rate n (%)	Stable disease n (%)	Progressive disease n (%)
IHC 2/3 (n = 30)	13 (43.3) (95% Cl: 25.5–62.6)	8 (26.7)	8 (26.7)
IHC 3 (n = 10)	5 (50.0) (95% CI: 22.2–77.8)	2 (20.0)	3 (30.0)
IHC 2 (<i>n</i> = 20)	8 (40.0) (95% CI: 20.9–63.9)	6 (30.0)	5 (25.0)
IHC 0/1 (n = 35)	4 (11.4) (95% CI: 4.0–26.3)	13 (37.1)	13 (37.1)
IHC 1 (n = 23)	3 (13.0) (95% Cl: 3.7–31.7)	8 (34.8)	8 (34.8)
IHC 0 (n = 12)	1 (8.3) (95% CI: 0.4–34.9)	5 (41.7)	5 (41.7)


Powles, Nature 2014

PD-L1 inhibition in refractory urothelial cancers



Powles, Nature 2014

KEYNOTE-012: Pembrolizumab Maximum Percent Change From Baseline in Target Lesions



RECIST v1.1, Central Review.

Analysis cutoff date: March 23, 2015.

11


SLIDES ARE THE PROPERTY OF THE AUTHOR. PERMISSION REQUIRED FOR REUSE.

PRESENTED AT: ASCO Annual '15 Meeting

With kind permission from E. Plimack

KEYNOTE-012: Pembrolizumab

Treatment Exposure and Response Duration





With kind permission from E. Plimack

Outline


- 1. General Principles Immunotherapy
- 2. Urothelial Carcinomas
- 3. Renal Cell Carcinoma
- 4. Prostate Cancer

Renal Cell Cancers





- Cytokine Therapies: IL-2 & IFN-alpha
- Tyrosine Kinase Inhibitors
- Checkpoint Inhibitors: Ipilimumab and PD-1
- Vaccine Therapy: AGS-003



Low Dose

(Fail/Total = 69/92)

36

48

60

72

Survival Time (months)

84

96

0.1

0.0

0

12 24

arms. + indicates response is ongoing.

Abbreviations: IV, intravenous; IL-2, interleukin-2; CR, complete response; PR, partial response.

720,000 U/kg vs. 72,000 U/kg

Yang, JCO 2003

108 120 132

Summary of RCC Clinical Trials


		Therapy	Alternative
First Line	Good px	Sunitnib or Pazopanib	Sorafenib
		IFN + bev or HD-IL2	
	Poor px	Temsirolimus	
Second	Cytokine	Sorafenib	Sunitinib
Line	Refractory	Pazopanib	
	VEGF(R) or	Everolimus	Sequential TKIs
	mTOR Refractory	Axitinib	
Non-Clear		Temsirolimus	
Cell		Sunitinib	
		Everolimus	

Nivolumab in RCC

Objective responses 0.3 mg/kg (n=60) 2 mg/kg (n=54) 10 mg/kg (n=54) 100 Best change in tumor volume from baseline (%) 52-10-10-01-% Best response % **Best response Best response** % 2 2 CR CR 0 CR 75-PR 18 PR PR 20 20 43 Stable 37 Stable Stable 44 33 PD 40 PD 32 PD 50 2 3 NE NE NE 4 25 -25--50 ORR^a = 22% ORR^a = 20% ORR^a = 20% -75-*ORR defined by RECIST v1.1; data cutoff May 15, 2013. CR, complete response; PR, partial response; PD, progressive disease; NE, not evaluable


With kind permission from R. Motzer

Nivolumab in RCC




With kind permission from R. Motzer

CheckMate 016



With kind permission from H. Hammers

CheckMate 016




With kind permission from H. Hammers


Active phase 3 studies in RCC

- CheckMate phase 3 RCC
 Ipilimumab + Nivolumab vs. sunitnib
 First line metastatic RCC
- ADAPT
 - Sunitinib +/- AGS-003 (autologous dendritic cell vaccine)

Open and accruing at CSMC

AGS-003: mechanism of action





Amin et al, J Immunother Cancer. 2015; 3: 14.


Outline

- 1. General Principles Immunotherapy
- 2. Urothelial Carcinomas
- 3. Renal Cell Carcinoma
- 4. Prostate Cancer


Prostate Cancer Systemic Therapy

- Androgen receptor inhibition
 - First line castration
 - Surgical
 - LHRH analogs
 - Next generation hormonal therapy
 - Androgen biosynthesis: abiraterone
 - Non-steroidal anti-androgens: bicalutamide, enzalutamide
- Cytotoxic chemotherapy: docetaxel, cabaziatxel
- Radionucleides: radium-223


Clinical States Model (2015)



Prostate Cancer Therapy: soon to come




Prostate Cancer Immunotherapies




Nature Reviews | Cancer

Sipuleucel-T

- First FDA-approved immunotherapy for prostate cancer.
- PAP-GMCSF and dendritic cells




Prostate Cancer Sipuleucel T VF: virus-based vaccine



Sipuleucel T had a median overall survival that was 8.5 months longer than the control group (25.1 versus 16.6 months) and a 44% reduction in the risk of death.

Scientific rationale for combination therapy with Sipuleucel T (hormone therapies, immune checkpoints inhibitor)

Sipuleucel T improves overall survival in mCRPC



Key Takeaways

- Bladder cancer:
 - BCG immune therapy is a standard treatment
 - Checkpoints inhibitors show great promise that needs to be developed in phase 3 trials
- Kidney cancer:
 - HD IL-2 (though not FDA approved) is an effective and historic treatment
 - Both vaccines and checkpoint inhibitors are developing strategies that show great promise
- Prostate cancer:
 - Dendritic cell therapy is effective
 - Other treatments are in active development